Valneva SE (VALN)
| Previous close | 7.26 |
| Open | 7.21 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 7.21 - 7.26 |
| 52-week range | 6.58 - 15.28 |
| Volume | |
| Avg. volume | 10,185 |
| Market cap | 504.428M |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.41 |
| Earnings date | 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.12 |
ZacksCan Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 149% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Globe NewswireCEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine
Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ®Funding will support clinical trials in vulnerable groups, such as children and pregnant women Partnership will also support technology transfer to an additional manufacturer to supply IXCHIQ® to Asian LMICsIXCHIQ® is already approved for use in adults 18 years of age and older in the U.S., Canada and Europe Oslo, Norway, and Saint-Herblain, France, July 22, 2024—The Coalition
BenzingaPfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
On Wednesday, Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Lyme disease is a bacterial infection that can be spread to humans by infected ticks. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025. "VLA15, the Lyme disease vaccine candidate we are co-developing wit
